SynthesisBMC cancer2019

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Bobo Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.